AbbVie (ABBV) and Xilio Therapeutics (XLO) said Wednesday they are collaborating and have signed an option-to-license agreement to develop tumor-activated, antibody-based immunotherapies, including masked T-cell engagers.
The companies said they will combine Xilio's tumor-activation technology with AbbVie's research and development efforts in oncology.
As part of the deal, Xilio will receive $52 million upfront, including a $10 million equity investment, the companies said, adding that Xilio could also earn up to $2.1 billion in milestone payments plus royalties.
Shares of Xilio Therapeutics soared 120% in recent premarket activity, while AbbVie shares were up 0.1%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。